About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in North Carolina | 137 Studies

Clinical Trials LymphomaNorth Carolina

Lymphoma Clinical Trials in North Carolina

Find 137 clinical trials for lymphoma near North Carolina. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in North Carolina

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 101-120 of 137 trials

CompletedVELCADE in Subjects With Relapsed or Refractory Mantle Cell LymphomaThe purpose of this study is to find out whether treatment with VELCADE will increase the time it takes for lymphoma to get worse.NCT00063713·Birmingham, Alabama and 34 others

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

Active not recruitingStudy of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular LymphomaFollicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes.NCT05409066·Tucson, Arizona and 272 others

CompletedReduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other DiseaseRATIONALE: Giving low doses of chemotherapy, such as busulfan and fludarabine, before a donor stem cell transplant helps stop the growth of cancer and abnormal cells.NCT00448201·Chapel Hill, North Carolina

Active not recruitingA Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaB-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections).NCT06508658·Duarte, California and 175 others

CompletedChemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic CancerRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.NCT00003661·Gainesville, Florida and 16 others

CompletedEfficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid ArthritisThe primary objective of this study was to evaluate the long-term safety and tolerability of olokizumab (OKZ) 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or…NCT03120949·Mesa, Arizona and 238 others

CompletedDouble Cord Versus Haploidentical (BMT CTN 1101)Hematopoietic cell transplants (HCT)are one treatment option for people with leukemia or lymphoma.NCT01597778·Birmingham, Alabama and 38 others

RecruitingA Study of AC676 for the Treatment of Relapsed/Refractory B-Cell MalignanciesThis clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies.NCT05780034·Denver, Colorado and 8 others

CompletedA Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell LymphomaThis Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plus R-CHP versus R-CHOP in…NCT03274492·Birmingham, Alabama and 208 others

TerminatedPhase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCLAFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts.NCT05883449·Birmingham, Alabama and 14 others

CompletedA Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHLThis is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.NCT03740529·Scottsdale, Arizona and 55 others

CompletedInduction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin LymphomaThe standard chemotherapy for Hodgkin lymphoma is called ABVD which is a combination of 4 chemotherapy drugs (doxorubicin, bleomycin, vinblastine, and dacarbazine).NCT01578967·Duarte, California and 5 others

RecruitingCD30 CAR for Relapsed/Refractory CD30+ T Cell LymphomaThis is a research study to determine the safety and tolerability of ATLCAR.CD30 for treating relapsed/refractory Peripheral T Cell Lymphoma.NCT04083495·Chapel Hill, North Carolina and 1 other

TerminatedA Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell LymphomasThis phase I/Ib study is designed to establish the safety and maximum tolerated dose (MTD, which will also be the recommended phase II dose (RP2D)) of the aurora kinase A…NCT02700022·Duarte, California and 1 other

SuspendedGM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell LymphomaRATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, work in different ways to stop the growth of cancer cells, either by…NCT00324831·Beverly Hills, California and 1 other

CompletedS0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin LymphomaRATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 tositumomab, can find cancer cells and carry cancer-killing substances to them without harming normal cells.NCT00770224·Mobile, Alabama and 113 others

RecruitingCognition, Flavonoids, Exercise, Gut MicrobiomeThis NIH project will examine the effects of routine flavonoid-rich blueberry intake (12-weeks), combined with or in the absence of regular moderate exercise, on cognitive…NCT06495190·Kannapolis, North Carolina

WithdrawnAdministration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer.NCT01316146·Chapel Hill, North Carolina and 2 others

TerminatedSafety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCLThe purpose of this study is to evaluate the safety and tolerability of MT-3724 in subjects with relapsed or refractory B-Cell NHL or relapsed and refractory CLL (Part 1 only) and…NCT02361346·Tucson, Arizona and 40 others

CompletedStudy of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's LymphomaThe purpose of this study is to determine if the combination of VELCADE and rituximab improves progression free survival relative to rituximab alone in patients with relapsed or…NCT00312845·Opelika, Alabama and 205 others

PreviousPage 6 of 7Next

Other Conditions in North Carolina

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia